The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2017 | The evolution of cancer supportive care
Sam Ahmedzai, MBChB, MRCP, FRCPS, FRCP, from the University of Sheffield talks about the evolution of cancer supportive care over the last 10-15 years. The discipline was initially focused on the treatment of chemotherapy-induced nausea and vomiting. This then extended to treating chemotherapy-induced peripheral neuropathy and other symptoms such as fatigue and post-surgical pain. Nowadays, with new biological treatments and new forms of toxicities, supportive care addresses many side effects in different organs, including cutaneous and neurological side effects. It is now even more important for oncologists to not only consider treatment effectiveness, but also the impact that a treatment can have on the patients. Prof Ahmedzai argues that supportive care needs to work alongside oncology and that supportive care makes excellent cancer care possible.
Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
